HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
Jump to navigation
Jump to search
| [unchecked revision] | [unchecked revision] |
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content | |+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content | ||
|- | |- | ||
!Disease (5th Edition)!!Page Type!!Author!!Date Assigned to Author!!Target Completion Date!!Author Content (Pending or Complete)!!Date Completed by Author!!Associate Editor!!Date of Last Editor Review | !Disease (5th Edition)!!Page Type!!Author (5th edition)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Author Content (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review!!Notes | ||
!Correlated Prior Disease Name (4th Edition)! | !Correlated Prior Disease Name (4th Edition) | ||
!Correlated Prior Author (4th Edition) | |||
|- | |- | ||
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS) | |CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS) | ||
| Line 10: | Line 11: | ||
| | | | ||
----<br /> | ----<br /> | ||
| | |||
| | | | ||
| | | | ||
| Line 19: | Line 21: | ||
| | | | ||
|- | |- | ||
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| | |Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| | |Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Chronic myeloid leukaemia||Disease||Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||FQR|| | |Chronic myeloid leukaemia||Disease||Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Chronic neutrophilic leukaemia||Disease||Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally|| || || || ||FQR|| | |Chronic neutrophilic leukaemia||Disease||Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Chronic eosinophilic leukaemia||Disease||Chelsea D. Kramish; Daynna J.Wolff Pending Review*|| || || || ||FQR|| | |Chronic eosinophilic leukaemia||Disease||Chelsea D. Kramish; Daynna J.Wolff Pending Review*|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Polycythaemia vera||Disease||Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center|| || || || ||FQR|| | |Polycythaemia vera||Disease||Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| | |Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| | |Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories|| || || || ||FQR|| | |Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| | |Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| | |Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| | |Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| | |Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| | |Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| | |Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| | |Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| | |Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| | |Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| | |Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| | |Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| | |Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| | |Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| | |Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| | |Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia|| || || || ||FQR|| | |Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| | |Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| | |Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| | |Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| | |Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| | |Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| | |Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| | |Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Acute promyelocytic leukaemia with PML::RARA fusion | |Acute promyelocytic leukaemia with PML::RARA fusion | ||
| Line 123: | Line 157: | ||
| | | | ||
|Jennelle Hodge (JH)/ Malini Sathanoori (MS) | |Jennelle Hodge (JH)/ Malini Sathanoori (MS) | ||
| | |||
| | | | ||
| | | | ||
| Line 135: | Line 170: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 147: | Line 183: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 159: | Line 196: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 171: | Line 209: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 183: | Line 222: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 195: | Line 235: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 207: | Line 248: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 219: | Line 261: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 231: | Line 274: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 243: | Line 287: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 255: | Line 300: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 267: | Line 313: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 279: | Line 326: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 291: | Line 339: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 303: | Line 352: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 315: | Line 365: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 327: | Line 378: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 339: | Line 391: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 351: | Line 404: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 363: | Line 417: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 375: | Line 430: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 387: | Line 443: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 399: | Line 456: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 411: | Line 469: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 423: | Line 482: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 435: | Line 495: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 447: | Line 508: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 459: | Line 521: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 471: | Line 534: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 483: | Line 547: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 495: | Line 560: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 507: | Line 573: | ||
| | | | ||
|JH_MS | |JH_MS | ||
| | |||
| | | | ||
| | | | ||
| Line 516: | Line 583: | ||
| | | | ||
----<br /> | ----<br /> | ||
| | |||
| | | | ||
| | | | ||
| Line 533: | Line 601: | ||
| | | | ||
|Greg Corboy (GC) | |Greg Corboy (GC) | ||
| | |||
| | | | ||
| | | | ||
| Line 545: | Line 614: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 557: | Line 627: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 569: | Line 640: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 581: | Line 653: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 593: | Line 666: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 605: | Line 679: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 617: | Line 692: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 629: | Line 705: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 641: | Line 718: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 653: | Line 731: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 662: | Line 741: | ||
| | | | ||
----<br /> | ----<br /> | ||
| | |||
| | | | ||
| | | | ||
| Line 679: | Line 759: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 691: | Line 772: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 703: | Line 785: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 715: | Line 798: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 727: | Line 811: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 739: | Line 824: | ||
| | | | ||
|Holli Drendel (HD) | |Holli Drendel (HD) | ||
| | |||
| | | | ||
| | | | ||
| Line 751: | Line 837: | ||
| | | | ||
|HD | |HD | ||
| | |||
| | | | ||
| | | | ||
| Line 763: | Line 850: | ||
| | | | ||
|HD | |HD | ||
| | |||
| | | | ||
| | | | ||
| Line 775: | Line 863: | ||
| | | | ||
|HD | |HD | ||
| | |||
| | | | ||
| | | | ||
| Line 787: | Line 876: | ||
| | | | ||
|HD | |HD | ||
| | |||
| | | | ||
| | | | ||
| Line 799: | Line 889: | ||
| | | | ||
|HD | |HD | ||
| | |||
| | | | ||
| | | | ||
| Line 811: | Line 902: | ||
| | | | ||
|HD | |HD | ||
| | |||
| | | | ||
| | | | ||
| Line 823: | Line 915: | ||
| | | | ||
|HD | |HD | ||
| | |||
| | | | ||
| | | | ||
| Line 835: | Line 928: | ||
| | | | ||
|HD | |HD | ||
| | |||
| | | | ||
| | | | ||
| Line 847: | Line 941: | ||
| | | | ||
|HD | |HD | ||
| | |||
| | | | ||
| | | | ||
| Line 859: | Line 954: | ||
| | | | ||
|HD | |HD | ||
| | |||
| | | | ||
| | | | ||
| Line 871: | Line 967: | ||
| | | | ||
|HD | |HD | ||
| | |||
| | | | ||
| | | | ||
| Line 883: | Line 980: | ||
| | | | ||
|HD | |HD | ||
| | |||
| | | | ||
| | | | ||
| Line 895: | Line 993: | ||
| | | | ||
|HD | |HD | ||
| | |||
| | | | ||
| | | | ||
| Line 900: | Line 999: | ||
|- | |- | ||
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG) | |Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG) | ||
| || | |||
| | |||
| | | | ||
|- | |- | ||
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD|| || || || ||SG|| | |Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD|| || || || ||SG|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| | |Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| | |Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| | |Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli | |Splenic B-cell lymphoma/leukaemia with prominent nucleoli | ||
| Line 923: | Line 1,027: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| Line 935: | Line 1,040: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| Line 947: | Line 1,053: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| Line 959: | Line 1,066: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| Line 971: | Line 1,079: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| Line 983: | Line 1,092: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| Line 995: | Line 1,105: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| Line 1,007: | Line 1,118: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| Line 1,019: | Line 1,131: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| Line 1,031: | Line 1,144: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| Line 1,043: | Line 1,157: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| Line 1,055: | Line 1,170: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| Line 1,067: | Line 1,183: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| Line 1,079: | Line 1,196: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| Line 1,091: | Line 1,209: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| | |Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| | |T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| | |Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| | |ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| | |Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| | |High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| | |Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| | |EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| | |Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| | |Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| | |Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| | |Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| | |Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| | |Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| | |Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| | |Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| | |Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| | |High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| | |Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Primary effusion lymphoma||Disease|| || || || || ||GC|| | |Primary effusion lymphoma||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| | |KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| | |KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| | |Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| | |Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| | |EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| | |Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| | |Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| | |Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| | |Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Cold agglutinin disease | |Cold agglutinin disease | ||
| Line 1,190: | Line 1,338: | ||
| | | | ||
|SG | |SG | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| | |IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| | |Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG | |Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG | ||
| || | |||
| | |||
| | | | ||
|- | |- | ||
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG | |Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG | ||
| || | |||
| | |||
| | | | ||
|- | |- | ||
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG | |Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG | ||
| || | |||
| | |||
| | | | ||
|- | |- | ||
|Mu heavy chain disease||Disease|| || || || || ||SG | |Mu heavy chain disease||Disease|| || || || || ||SG | ||
| || | |||
| | |||
| | | | ||
|- | |- | ||
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA|| || || || ||SG | |Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA|| || || || ||SG | ||
| || | |||
| | |||
| | | | ||
|- | |- | ||
|Alpha heavy chain disease||Disease|| || || || || ||SG | |Alpha heavy chain disease||Disease|| || || || || ||SG | ||
| || | |||
| | |||
| | | | ||
|- | |- | ||
|Plasmacytoma||Disease|| || || || || ||SG | |Plasmacytoma||Disease|| || || || || ||SG | ||
| || | |||
| | |||
| | | | ||
|- | |- | ||
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG | |Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG | ||
| || | |||
| | |||
| | | | ||
|- | |- | ||
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD|| || || || ||SG | |Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD|| || || || ||SG | ||
| || | |||
| | |||
| | | | ||
|- | |- | ||
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) | |CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) | ||
| Line 1,241: | Line 1,401: | ||
| | | | ||
----<br /> | ----<br /> | ||
| | |||
| | | | ||
| | | | ||
| Line 1,251: | Line 1,412: | ||
|- | |- | ||
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK) | |Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK) | ||
| || | |||
| | |||
| | | | ||
|- | |- | ||
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| | |Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| | |Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| | |T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Early T-precursor lymphoblastic leukaemia / lymphoma | |Early T-precursor lymphoblastic leukaemia / lymphoma | ||
| Line 1,271: | Line 1,436: | ||
| | | | ||
|HD | |HD | ||
| | |||
| | | | ||
| | | | ||
| Line 1,283: | Line 1,449: | ||
| | | | ||
|SK | |SK | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| | |T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| | |NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center|| || || || ||SK|| | |Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| | |Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| | |Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| | |Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| | |Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| | |Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| | |Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| | |Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| | |Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| | |Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| | |Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| | |Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| | |Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| | |Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| | |Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| | |Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| | |ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| | |ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center|| || || || ||SK|| | |Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| | |Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| | |Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD|| || || || ||SK|| | |Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| | |Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| | |EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| | |Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| | |Severe mosquito bite allergy||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| | |Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| | |Systemic chronic active EBV disease||Disease|| || || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| | |Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| || | ||
| | | | ||
| | |||
|- | |- | ||
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES) | |CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES) | ||
| Line 1,391: | Line 1,591: | ||
| | | | ||
----<br /> | ----<br /> | ||
| | |||
| | | | ||
| | | | ||
| Line 1,408: | Line 1,609: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 1,420: | Line 1,622: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 1,432: | Line 1,635: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 1,444: | Line 1,648: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 1,456: | Line 1,661: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 1,468: | Line 1,674: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 1,480: | Line 1,687: | ||
| | | | ||
|GC | |GC | ||
| | |||
| | | | ||
| | | | ||
| Line 1,489: | Line 1,697: | ||
| | | | ||
----<br /> | ----<br /> | ||
| | |||
| | | | ||
| | | | ||
| Line 1,498: | Line 1,707: | ||
| | | | ||
|- | |- | ||
|Fanconi anaemia||Disease|| || || || || ||NA|| | |Fanconi anaemia||Disease|| || || || || ||NA|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Bloom syndrome||Disease|| || || || || ||NA|| | |Bloom syndrome||Disease|| || || || || ||NA|| || | ||
| | | | ||
| | |||
|- | |- | ||
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| | |Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| || | ||
| | | | ||
| | |||
|- | |- | ||
|RASopathies||Disease|| || || || || ||NA|| | |RASopathies||Disease|| || || || || ||NA|| || | ||
| | | | ||
| | |||
|} | |} | ||
Revision as of 14:46, 17 December 2023
| Disease (5th Edition) | Page Type | Author (5th edition) | Date Assigned to Author (5th Edition) | Target Completion Date (5th Edition) | Author Content (5th Edition)(Pending or Complete) | Date Completed by Author (5th Edition) | Associate Editor | Date of Last Editor Review | Notes | Correlated Prior Disease Name (4th Edition) | Correlated Prior Author (4th Edition) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS) |
|
|
|||||||||
| Clonal haematopoiesis | Disease | Fabiola Quintero-Rivera (FQR) | |||||||||
| Clonal cytopenias of undetermined significance | Disease | FQR | |||||||||
| Chronic myeloid leukaemia | Disease | Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | FQR | ||||||||
| Chronic neutrophilic leukaemia | Disease | Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine **contributed equally | FQR | ||||||||
| Chronic eosinophilic leukaemia | Disease | Chelsea D. Kramish; Daynna J.Wolff Pending Review* | FQR | ||||||||
| Polycythaemia vera | Disease | Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | FQR | ||||||||
| Essential thrombocythaemia | Disease | Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | FQR | ||||||||
| Primary myelofibrosis | Disease | T. Niroshi Senaratne, UCLA | FQR | ||||||||
| Juvenile myelomonocytic leukaemia | Disease | Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories | FQR | ||||||||
| Myeloproliferative neoplasm, NOS | Disease | Thomas Lee, MD, PhD, University of California, Los Angeles | FQR | ||||||||
| Cutaneous mastocytosis | Disease | S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | FQR | ||||||||
| Systemic mastocytosis | Disease | Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University | FQR | ||||||||
| Mast cell sarcoma | Disease | Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | FQR | ||||||||
| Myelodysplastic neoplasm with low blasts and 5q deletion | Disease | FQR | |||||||||
| Myelodysplastic neoplasm with low blasts and SF3B1 mutation | Disease | FQR | |||||||||
| Myelodysplastic neoplasm with biallelic TP53 inactivation | Disease | FQR | |||||||||
| Myelodysplastic neoplasm with low blasts | Disease | FQR | |||||||||
| Myelodysplastic neoplasm, hypoplastic | Disease | FQR | |||||||||
| Myelodysplastic neoplasm with increased blasts | Disease | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. | FQR | ||||||||
| Childhood myelodysplastic neoplasm with low blasts | Disease | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. | FQR | ||||||||
| Childhood myelodysplastic neoplasm with increased blasts | Disease | Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. | FQR | ||||||||
| Chronic myelomonocytic leukaemia | Disease | Linsheng Zhang, MD, PhD | FQR | ||||||||
| Myelodysplastic/myeloproliferative neoplasm with neutrophilia | Disease | Linsheng Zhang, MD, PhD | FQR | ||||||||
| Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis | Disease | Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | FQR | ||||||||
| Myelodysplastic/myeloproliferative neoplasm, NOS | Disease | Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | FQR | ||||||||
| Myeloid/lymphoid neoplasm with PDGFRA rearrangement | Disease | Jay Alden, DO | FQR | ||||||||
| Myeloid/lymphoid neoplasm with PDGFRB rearrangement | Disease | Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD | FQR | ||||||||
| Myeloid/lymphoid neoplasm with FGFR1 rearrangement | Disease | Yanna Ding, MD PhD | FQR | ||||||||
| Myeloid/lymphoid neoplasm with JAK2 rearrangement | Disease | Jessica Snider, M.D. and Daynna J. Wolff, PhD | FQR | ||||||||
| Myeloid/lymphoid neoplasm with FLT3 rearrangement | Disease | FQR | |||||||||
| Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion | Disease | FQR | |||||||||
| Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes | Disease | FQR | |||||||||
| Acute promyelocytic leukaemia with PML::RARA fusion | Disease | Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D. | Jennelle Hodge (JH)/ Malini Sathanoori (MS) | ||||||||
| Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion | Disease | Christine Bryke, MD Beth Israel Deaconess Medical Center, Boston, MA |
JH_MS | ||||||||
| Acute myeloid leukaemia with CBFB::MYH11 fusion | Disease | Christine Bryke, MD Beth Israel Deaconess Medical Center, Boston, MA |
JH_MS | ||||||||
| Acute myeloid leukaemia with DEK::NUP214 fusion | Disease | JH_MS | |||||||||
| Acute myeloid leukaemia with RBM15::MRTFA fusion | Disease | Jennelle C. Hodge, PhD, FACMG | JH_MS | ||||||||
| Acute myeloid leukaemia with BCR::ABL1 fusion | Disease | Kay Weng Choy MBBS, Monash Medical Centre | JH_MS | ||||||||
| Acute myeloid leukaemia with KMT2A rearrangement | Disease | Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D. | JH_MS | ||||||||
| Acute myeloid leukaemia with MECOM rearrangement | Disease | JH_MS | |||||||||
| Acute myeloid leukaemia with NUP98 rearrangement | Disease | JH_MS | |||||||||
| Acute myeloid leukaemia with NPM1 mutation | Disease | Xinjie Xu, PhD, FACMG | JH_MS | ||||||||
| Acute myeloid leukaemia with CEBPA mutation | Disease | Paul Defazio, MSc, Monash Health | JH_MS | ||||||||
| Acute myeloid leukaemia, myelodysplasia-related | Disease | Fei Yang, MD, FACMG Oregon Health & Science University, Portland, OR |
JH_MS | ||||||||
| Acute myeloid leukaemia with other defined genetic alterations | Disease | JH_MS | |||||||||
| Acute myeloid leukaemia with minimal differentiation | Disease | Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | JH_MS | ||||||||
| Acute myeloid leukaemia without maturation | Disease | Jennelle C. Hodge, PhD, FACMG | JH_MS | ||||||||
| Acute myeloid leukaemia with maturation | Disease | Jennelle C. Hodge, PhD, FACMG | JH_MS | ||||||||
| Acute basophilic leukaemia | Disease | Ashwini Yenamandra PhD FACMG | JH_MS | ||||||||
| Acute myelomonocytic leukaemia | Disease | Fei Yang, MD, FACMG Oregon Health & Science University, Portland, OR |
JH_MS | ||||||||
| Acute monocytic leukaemia | Disease | Fei Yang, MD, FACMG Oregon Health & Science University, Portland, OR |
JH_MS | ||||||||
| Acute erythroid leukaemia | Disease | Ashwini Yenamandra PhD FACMG | JH_MS | ||||||||
| Acute megakaryoblastic leukaemia | Disease | Fei Yang, MD, FACMG Oregon Health & Science University, Portland, OR |
JH_MS | ||||||||
| Myeloid sarcoma | Disease | Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine | JH_MS | ||||||||
| Myeloid neoplasm post cytotoxic therapy | Disease | Shawn A. Silver, DO, Shashi Shetty, Ph.D. | JH_MS | ||||||||
| Myeloid neoplasms associated with germline predisposition | Disease | JH_MS | |||||||||
| Myeloid proliferations associated with Down syndrome | Disease | Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | JH_MS | ||||||||
| Mixed-phenotype acute leukaemia with BCR::ABL1 fusion | Disease | Tracy Tucker, PhD, FCCMG | JH_MS | ||||||||
| Mixed-phenotype acute leukaemia with KMT2A rearrangement | Disease | Tracy Tucker, PhD, FCCMG | JH_MS | ||||||||
| Acute leukaemia of ambiguous lineage with other defined genetic alterations | Disease | JH_MS | |||||||||
| Mixed-phenotype acute leukaemia, B/myeloid | Disease | Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD | JH_MS | ||||||||
| Mixed-phenotype acute leukaemia, T/myeloid | Disease | Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | JH_MS | ||||||||
| Mixed-phenotype acute leukaemia, rare types | Disease | Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | JH_MS | ||||||||
| Acute leukaemia of ambiguous lineage, NOS | Disease | JH_MS | |||||||||
| Acute undifferentiated leukaemia | Disease | Amelia Nakanishi, MD and Shashi Shetty, PhD | JH_MS | ||||||||
| CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS) |
|
|
|||||||||
| Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm | Disease | Greg Corboy (GC) | |||||||||
| Blastic plasmacytoid dendritic cell neoplasm | Disease | Hao Liu, MD and Daynna J. Wolff, PhD | GC | ||||||||
| Langerhans cell histiocytosis | Disease | Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | GC | ||||||||
| Langerhans cell sarcoma | Disease | Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland | GC | ||||||||
| Indeterminate dendritic cell tumour | Disease | GC | |||||||||
| Interdigitating dendritic cell sarcoma | Disease | GC | |||||||||
| Juvenile xanthogranuloma | Disease | GC | |||||||||
| Erdheim-Chester disease | Disease | GC | |||||||||
| Rosai-Dorfman Disease | Disease | GC | |||||||||
| ALK-positive histiocytosis | Disease | GC | |||||||||
| Histiocytic sarcoma | Disease | Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic | GC | ||||||||
| CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) |
|
|
|||||||||
| Reactive B-cell rich lymphoid proliferations that can mimic lymphoma | Disease | GC | |||||||||
| IgG4-related disease | Disease | GC | |||||||||
| Unicentric Castleman disease | Disease | GC | |||||||||
| Idiopathic multicentric Castleman disease | Disease | GC | |||||||||
| KSHV/HHV8-associated multicentric Castleman disease | Disease | Sudha Arumugam, MD | GC | ||||||||
| B-lymphoblastic leukaemia/lymphoma | Disease | Holli Drendel (HD) | |||||||||
| B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy | Disease | Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | HD | ||||||||
| B-lymphoblastic leukaemia/lymphoma with hypodiploidy | Disease | Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG | HD | ||||||||
| B-lymphoblastic leukaemia/lymphoma with iAMP21 | Disease | Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte | HD | ||||||||
| B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion | Disease | Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | HD | ||||||||
| B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features | Disease | Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine | HD | ||||||||
| B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement | Disease | Yassmine Akkari Nicolas Millan | HD | ||||||||
| B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion | Disease | Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma | HD | ||||||||
| B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features | Disease | HD | |||||||||
| B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion | Disease | Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO | HD | ||||||||
| B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion | Disease | Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO | HD | ||||||||
| B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion | Disease | HD | |||||||||
| B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations | Disease | HD | |||||||||
| B-lymphoblastic leukaemia/lymphoma, NOS | Disease | HD | |||||||||
| Monoclonal B-cell lymphocytosis | Disease | Shivani Golem (SG) | |||||||||
| Chronic lymphocytic leukaemia/small lymphocytic lymphoma | Disease | Jamie Nagy, PhD, University of Iowa Honey Reddi, PhD | SG | ||||||||
| Hairy cell leukaemia | Disease | *Snehal Patel, MD, PhD | SG | ||||||||
| Splenic marginal zone lymphoma | Disease | *Snehal Patel, MD, PhD | SG | ||||||||
| Splenic diffuse red pulp small B-cell lymphoma | Disease | *Snehal Patel, MD, PhD | SG | ||||||||
| Splenic B-cell lymphoma/leukaemia with prominent nucleoli | Disease | *Snehal Patel, MD, PhD | SG | ||||||||
| Lymphoplasmacytic lymphoma | Disease | Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | SG | ||||||||
| Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue | Disease | SG | |||||||||
| Primary cutaneous marginal zone lymphoma | Disease | SG | |||||||||
| Nodal marginal zone lymphoma | Disease | Andrew Ly, DO and Shivani Golem, PhD, FACMG | SG | ||||||||
| Paediatric nodal marginal zone lymphoma | Disease | * Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD | SG | ||||||||
| In situ follicular B-cell neoplasm | Disease | Rachel D. Burnside, PhD, MBA, FACMGG | SG | ||||||||
| Follicular lymphoma | Disease | Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital Rachel D. Burnside, PhD, MBA, FACMG, University of Florida | SG | ||||||||
| Paediatric-type follicular lymphoma | Disease | *Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG | SG | ||||||||
| Duodenal-type follicular lymphoma | Disease | SG | |||||||||
| Primary cutaneous follicle centre lymphoma | Disease | Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG | SG | ||||||||
| In situ mantle cell neoplasm | Disease | Rina Kansal, MD; Versiti Blood Center of Wisconsin | SG | ||||||||
| Mantle cell lymphoma | Disease | * Mahsa Khanlari, MD * Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas | SG | ||||||||
| Leukaemic non-nodal mantle cell lymphoma | Disease | SG | |||||||||
| Transformations of indolent B-cell lymphomas | Disease | SG | |||||||||
| Diffuse large B-cell lymphoma, NOS | Disease | Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | GC | ||||||||
| T-cell/histiocyte-rich large B-cell lymphoma | Disease | GC | |||||||||
| Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements | Disease | Kate Berry, MBBS, BBus (Hons), Pathology Queensland | GC | ||||||||
| ALK-positive large B-cell lymphoma | Disease | Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | GC | ||||||||
| Large B-cell lymphoma with IRF4 rearrangement | Disease | *Afia Hasnain, MBBS, PhD | GC | ||||||||
| High grade B-cell lymphoma with 11q aberrations | Disease | Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | GC | ||||||||
| Lymphomatoid granulomatosis | Disease | GC | |||||||||
| EBV-positive diffuse large B-cell lymphoma | Disease | GC | |||||||||
| Diffuse large B-cell lymphoma associated with chronic inflammation | Disease | GC | |||||||||
| Fibrin-associated large B-cell lymphoma | Disease | GC | |||||||||
| Fluid overload-associated large B-cell lymphoma | Disease | GC | |||||||||
| Plasmablastic lymphoma | Disease | Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | GC | ||||||||
| Primary large B-cell lymphoma of immune-privileged sites | Disease | Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | GC | ||||||||
| Primary cutaneous diffuse large B-cell lymphoma, leg type | Disease | GC | |||||||||
| Intravascular large B-cell lymphoma | Disease | Kate Berry, MBBS, BBus (Hons), Pathology Queensland | GC | ||||||||
| Primary mediastinal large B-cell lymphoma | Disease | GC | |||||||||
| Mediastinal grey zone lymphoma | Disease | GC | |||||||||
| High-grade B-cell lymphoma, NOS | Disease | Aiko Otsubo, PhD, Indiana University | GC | ||||||||
| Burkitt lymphoma | Disease | Becky Leung, MBBS (Hons), BSc, Pathology Queensland | GC | ||||||||
| Primary effusion lymphoma | Disease | GC | |||||||||
| KSHV/HHV8-positive diffuse large B-cell lymphoma | Disease | GC | |||||||||
| KSHV/HHV8-positive germinotropic lymphoproliferative disorder | Disease | GC | |||||||||
| Hyperplasias arising in immune deficiency/dysregulation | Disease | GC | |||||||||
| Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation | Disease | Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI) | GC | ||||||||
| EBV-positive mucocutaneous ulcer | Disease | GC | |||||||||
| Lymphomas arising in immune deficiency / dysregulation | Disease | GC | |||||||||
| Inborn error of immunity-associated lymphoid proliferations and lymphomas | Disease | GC | |||||||||
| Classic Hodgkin lymphoma | Disease | Patricia V. Hernandez, M.D., Washington University School of Medicine | GC | ||||||||
| Nodular lymphocyte predominant Hodgkin lymphoma | Disease | GC | |||||||||
| Cold agglutinin disease | Disease | SG | |||||||||
| IgM monoclonal gammopathy of undetermined significance | Disease | SG | |||||||||
| Non-IgM monoclonal gammopathy of undetermined significance | Disease | SG | |||||||||
| Monoclonal gammopathy of renal significance | Disease | SG | |||||||||
| Immunoglobulin-related (AL) amyloidosis | Disease | Heather E. Williams, PhD, MS, PgD, ErCLG | SG | ||||||||
| Monoclonal immunoglobulin deposition disease | Disease | Chen Yang, MD, PhD, University of Michigan | SG | ||||||||
| Mu heavy chain disease | Disease | SG | |||||||||
| Gamma heavy chain disease | Disease | Manisha Brahmbhatt-Sutariya Asst. Professor, Dept. of Pathology and Human Anatomy Technical Supervisor, Clinical Genetics Laboratory Loma Linda University, Medical Center, CA | SG | ||||||||
| Alpha heavy chain disease | Disease | SG | |||||||||
| Plasmacytoma | Disease | SG | |||||||||
| Plasma cell myeloma / multiple myeloma | Disease | *Huan Mo, MD, MS *Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas | SG | ||||||||
| Plasma cell neoplasms with associated paraneoplastic syndrome | Disease | Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD | SG | ||||||||
| CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS) |
|
|
|||||||||
| Kikuchi-Fujimoto disease | Disease | Sumi Kitahara (SK) | |||||||||
| Autoimmune lymphoproliferative syndrome | Disease | SK | |||||||||
| Indolent T-lymphoblastic proliferation | Disease | SK | |||||||||
| T-lymphoblastic leukaemia / lymphoma, NOS | Disease | HD | |||||||||
| Early T-precursor lymphoblastic leukaemia / lymphoma | Disease | Fei Yang, MD, FACMG, Kaiser Permanente Northwest | HD | ||||||||
| T-prolymphocytic leukaemia | Disease | SK | |||||||||
| T-large granular lymphocytic leukaemia | Disease | *Michelle Don, MD, MS | SK | ||||||||
| NK-large granular lymphocytic leukaemia | Disease | Michelle Don, MD | SK | ||||||||
| Adult T-cell leukaemia/lymphoma | Disease | Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | SK | ||||||||
| Sezary syndrome | Disease | Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | SK | ||||||||
| Aggressive NK-cell leukaemia | Disease | Shanelle De Lancy, MD, Shashirekha Shetty, PhD | SK | ||||||||
| Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder | Disease | SK | |||||||||
| Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder | Disease | SK | |||||||||
| Mycosis fungoides | Disease | Jane Scribner, MD and Daynna J. Wolff, PhD | SK | ||||||||
| Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis | Disease | SK | |||||||||
| Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma | Disease | Theresa Spivey, MD, Shashirekha Shetty, PhD | SK | ||||||||
| Subcutaneous panniculitis-like T-cell lymphoma | Disease | SK | |||||||||
| Primary cutaneous gamma/delta T-cell lymphoma | Disease | SK | |||||||||
| Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma | Disease | SK | |||||||||
| Primary cutaneous peripheral T-cell lymphoma, NOS | Disease | SK | |||||||||
| Indolent T-cell lymphoma of the gastrointestinal tract | Disease | Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | SK | ||||||||
| Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract | Disease | SK | |||||||||
| Enteropathy-associated T-cell lymphoma | Disease | *Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | SK | ||||||||
| Monomorphic epitheliotropic intestinal T-cell lymphoma | Disease | Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | SK | ||||||||
| Intestinal T-cell lymphoma, NOS | Disease | Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) | SK | ||||||||
| Hepatosplenic T-cell lymphoma | Disease | *Michelle Don, MD, MS | SK | ||||||||
| ALK-positive anaplastic large cell lymphoma | Disease | SK | |||||||||
| ALK-negative anaplastic large cell lymphoma | Disease | Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | SK | ||||||||
| Breast implant-associated anaplastic large cell lymphoma | Disease | Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | SK | ||||||||
| Nodal TFH cell lymphoma, angioimmunoblastic-type | Disease | * Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG | SK | ||||||||
| Nodal TFH cell lymphoma, follicular-type | Disease | SK | |||||||||
| Nodal TFH cell lymphoma, NOS | Disease | Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | SK | ||||||||
| Peripheral T-cell lymphoma, NOS | Disease | SK | |||||||||
| EBV-positive nodal T- and NK-cell lymphoma | Disease | SK | |||||||||
| Extranodal NK/T-cell lymphoma | Disease | SK | |||||||||
| Severe mosquito bite allergy | Disease | SK | |||||||||
| Hydroa vacciniforme lymphoproliferative disorder | Disease | SK | |||||||||
| Systemic chronic active EBV disease | Disease | SK | |||||||||
| Systemic EBV-positive T-cell lymphoma of childhood | Disease | *Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA | SK | ||||||||
| CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES) |
|
|
|||||||||
| Follicular dendritic cell sarcoma | Disease | Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG | GC | ||||||||
| EBV-positive inflammatory follicular dendritic cell sarcoma | Disease | GC | |||||||||
| Fibroblastic reticular cell tumour | Disease | GC | |||||||||
| Intranodal palisaded myofibroblastoma | Disease | GC | |||||||||
| Littoral cell angioma | Disease | GC | |||||||||
| Splenic hamartoma | Disease | GC | |||||||||
| Sclerosing angiomatoid nodular transformation (SANT) of spleen | Disease | GC | |||||||||
| CHAPTER 7 (GENETIC TUMOUR SYNDROMES) |
|
|
|||||||||
| Fanconi anaemia | Disease | NA | |||||||||
| Bloom syndrome | Disease | NA | |||||||||
| Ataxia-telangiectasia syndrome | Disease | NA | |||||||||
| RASopathies | Disease | NA |